Regular cannabinoid use and inflammatory biomarkers: Systematic review and hierarchical meta-analysis.
Table of Contents
- Regular cannabinoid use and inflammatory biomarkers: Systematic review and hierarchical meta-analysis.
- FAQ
- Does regular cannabis use affect inflammatory markers in the body?
- Should I be concerned about inflammation if I use cannabis regularly?
- Are the anti-inflammatory effects of cannabis supported by clinical trials?
- Does cannabis use affect inflammation differently in people with psychiatric disorders?
- How reliable is this evidence for clinical decision-making?
- Read next
- FAQ
Regular cannabinoid use and inflammatory biomarkers: Systematic review and hierarchical meta-analysis.
Regular cannabinoid use was associated with higher anti-inflammatory biomarker levels in observational studies involving 54,382 participants.
This meta-analysis provides the first systematic synthesis of cannabinoid effects on inflammatory biomarkers across diverse populations. The finding of increased anti-inflammatory markers in cannabis users suggests a measurable immunomodulatory signal, though the clinical significance remains unclear.
With cannabis use rising for both medical and recreational purposes, understanding its inflammatory effects is clinically relevant for patient counseling. This data helps frame discussions about potential immune system interactions in cannabinoid users.
| Study Type | Systematic Review and Meta-Analysis |
| Population | 54,382 participants across 46 studies, including healthy populations and individuals with psychiatric disorders |
| Intervention | Regular cannabinoid use |
| Comparator | Non-users of cannabinoids |
| Primary Outcome | Peripheral inflammatory biomarkers |
| Key Finding | Cannabis use associated with higher anti-inflammatory biomarker levels in observational studies |
| Journal | Brain, Behavior, and Immunity |
| Year | 2025 |
Regular cannabinoid use appears associated with detectable changes in inflammatory biomarkers, specifically increases in anti-inflammatory markers. However, the clinical meaningfulness of these laboratory changes for health outcomes remains undefined.
The abstract does not establish whether these biomarker changes translate to meaningful clinical outcomes, disease risk modification, or therapeutic benefit. The direction and magnitude of effects from RCTs and prospective studies are not provided.
Observational studies cannot establish causation, and confounding by lifestyle factors, underlying conditions, or co-substance use may explain associations. The heterogeneity across 46 studies likely introduces significant methodological variability.
Cannabinoid use produces detectable changes in inflammatory biomarkers, but the clinical relevance remains uncertain. These findings support the biological plausibility of immune modulation but don’t establish therapeutic utility or safety implications.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
Does regular cannabis use affect inflammatory markers in the body?
Yes, this meta-analysis of 46 studies involving over 54,000 participants found that regular cannabis use is associated with higher levels of anti-inflammatory biomarkers. This suggests cannabis may have an anti-inflammatory effect at the systemic level, though the clinical significance of these changes requires further investigation.
Should I be concerned about inflammation if I use cannabis regularly?
Based on current evidence, regular cannabis use appears to be associated with increased anti-inflammatory rather than pro-inflammatory markers, which may actually be beneficial. However, individual responses can vary, and patients with existing inflammatory conditions should discuss cannabis use with their healthcare provider.
Are the anti-inflammatory effects of cannabis supported by clinical trials?
The study included data from randomized controlled trials, though the majority of evidence comes from observational studies. While the findings suggest anti-inflammatory effects, more high-quality clinical trials are needed to establish definitive therapeutic recommendations for inflammatory conditions.
Does cannabis use affect inflammation differently in people with psychiatric disorders?
The study specifically examined whether cannabinoids affect inflammation in both healthy populations and individuals with psychiatric disorders. However, the summary doesn’t provide clear distinctions between these groups, indicating more research is needed to understand population-specific effects.
How reliable is this evidence for clinical decision-making?
This systematic review and meta-analysis represents high-quality evidence synthesis from 46 studies with a large participant pool. However, the predominance of observational data means causation cannot be definitively established, and clinical applications should be considered carefully alongside other patient factors.
